August 6, 2012
American Medical News
This article discusses Assn. for Molecular Pathology v. U.S. Patent and Trademark Office et al., and looks to legal experts on their thoughts regarding what the "appeals judges appeared to show their hand during re-arguments." Finnegan senior counsel, David S. Forman, Ph.D., provided commentary. Dr. Forman stated he would be “very surprised if the federal circuit rules substantially different from the first decision.” He also said, “It is probable that it’ll go back to the Supreme Court because it’s so controversial. Because of Prometheus, there is more uncertainty as to what the Supreme Court might do with this.”
Commentary
Patent Strategy Could Shape Financing, Valuation and Risk in Offshore Energy Projects
June 30, 2026
Award/Ranking
Finnegan’s European Practices and Attorneys Highlighted in 2026 Managing IP Rankings
June 25, 2026
Press Release
BMW Obtains Preliminary Injunction Against Zync; Federal Court Orders Zync to Halt ITC Trade Secret
June 23, 2026
Award/Ranking
Six Finnegan Partners Recognized in the 2026 Lawdragon 500 Leading Global IP Lawyers
June 22, 2026
Commentary
U.S. Judge Rules Forum-Selection Clause Bars Zync from Pursuing ITC Trade Secret Case
June 15, 2026
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.